295 related articles for article (PubMed ID: 34656916)
1. Sudden death after inappropriate shocks of implantable cardioverter defibrillator in a catecholaminergic polymorphic ventricular tachycardia case with a novel RyR2 mutation.
Itoh H; Murayama T; Kurebayashi N; Ohno S; Kobayashi T; Fujii Y; Watanabe M; Ogawa H; Anzai T; Horie M
J Electrocardiol; 2021; 69():111-118. PubMed ID: 34656916
[TBL] [Abstract][Full Text] [Related]
2. Description of a novel RyR2 mutation in a juvenile patient with symptomatic catecholaminergic polymorphic ventricular tachycardia in sleep and during exercise: a case report.
Seidlmayer LK; Riediger F; Pagonas N; Nordbeck P; Ritter O; Sasko B
J Med Case Rep; 2018 Oct; 12(1):298. PubMed ID: 30296944
[TBL] [Abstract][Full Text] [Related]
3. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
Watanabe H; Knollmann BC
J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
[TBL] [Abstract][Full Text] [Related]
4. Clinical and molecular characterization of patients with catecholaminergic polymorphic ventricular tachycardia.
Priori SG; Napolitano C; Memmi M; Colombi B; Drago F; Gasparini M; DeSimone L; Coltorti F; Bloise R; Keegan R; Cruz Filho FE; Vignati G; Benatar A; DeLogu A
Circulation; 2002 Jul; 106(1):69-74. PubMed ID: 12093772
[TBL] [Abstract][Full Text] [Related]
5. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
Sy RW; Gollob MH; Klein GJ; Yee R; Skanes AC; Gula LJ; Leong-Sit P; Gow RM; Green MS; Birnie DH; Krahn AD
Heart Rhythm; 2011 Jun; 8(6):864-71. PubMed ID: 21315846
[TBL] [Abstract][Full Text] [Related]
6. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
Nozaki Y; Kato Y; Uike K; Yamamura K; Kikuchi M; Yasuda M; Ohno S; Horie M; Murayama T; Kurebayashi N; Horigome H
Circ J; 2020 Jan; 84(2):226-234. PubMed ID: 31875585
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
Pott C; Dechering DG; Reinke F; Muszynski A; Zellerhoff S; Bittner A; Köbe J; Wasmer K; Schulze-Bahr E; Mönnig G; Kotthoff S; Eckardt L
Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
[TBL] [Abstract][Full Text] [Related]
8. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
Roses-Noguer F; Jarman JW; Clague JR; Till J
Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
[TBL] [Abstract][Full Text] [Related]
9. A delayed diagnosis of catecholaminergic polymorphic ventricular tachycardia with a mutant of RYR2 at c.7580T>G for 6 years in a 9-year-old child.
Duan H; Lu Y; Yan S; Qiao L; Hua Y; Li Y; Zhou K; Wang C
Medicine (Baltimore); 2018 Apr; 97(16):e0368. PubMed ID: 29668588
[TBL] [Abstract][Full Text] [Related]
10. Postpacing abnormal repolarization in catecholaminergic polymorphic ventricular tachycardia associated with a mutation in the cardiac ryanodine receptor gene.
Nof E; Belhassen B; Arad M; Bhuiyan ZA; Antzelevitch C; Rosso R; Fogelman R; Luria D; El-Ani D; Mannens MM; Viskin S; Eldar M; Wilde AA; Glikson M
Heart Rhythm; 2011 Oct; 8(10):1546-52. PubMed ID: 21699856
[TBL] [Abstract][Full Text] [Related]
11. Sudden death in a young man with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
Pizzale S; Gollob MH; Gow R; Birnie DH
J Cardiovasc Electrophysiol; 2008 Dec; 19(12):1319-21. PubMed ID: 18554199
[TBL] [Abstract][Full Text] [Related]
12. A novel cardiac ryanodine receptor gene (RyR2) mutation in an athlete with aborted sudden cardiac death: a case of adult-onset catecholaminergic polymorphic ventricular tachycardia.
Arakawa J; Hamabe A; Aiba T; Nagai T; Yoshida M; Touya T; Ishigami N; Hisadome H; Katsushika S; Tabata H; Miyamoto Y; Shimizu W
Heart Vessels; 2015 Nov; 30(6):835-40. PubMed ID: 25092222
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
Wangüemert F; Bosch Calero C; Pérez C; Campuzano O; Beltran-Alvarez P; Scornik FS; Iglesias A; Berne P; Allegue C; Ruiz Hernandez PM; Brugada J; Pérez GJ; Brugada R
Heart Rhythm; 2015 Jul; 12(7):1636-43. PubMed ID: 25814417
[TBL] [Abstract][Full Text] [Related]
14. Identification of loss-of-function RyR2 mutations associated with idiopathic ventricular fibrillation and sudden death.
Zhong X; Guo W; Wei J; Tang Y; Liu Y; Zhang JZ; Tan VH; Zhang L; Wang R; Jones PP; Napolitano C; Priori SG; Chen SRW
Biosci Rep; 2021 Apr; 41(4):. PubMed ID: 33825858
[TBL] [Abstract][Full Text] [Related]
15. A novel ryanodine receptor mutation linked to sudden death increases sensitivity to cytosolic calcium.
Meli AC; Refaat MM; Dura M; Reiken S; Wronska A; Wojciak J; Carroll J; Scheinman MM; Marks AR
Circ Res; 2011 Jul; 109(3):281-90. PubMed ID: 21659649
[TBL] [Abstract][Full Text] [Related]
16. S4153R is a gain-of-function mutation in the cardiac Ca(2+) release channel ryanodine receptor associated with catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation.
Zhabyeyev P; Hiess F; Wang R; Liu Y; Wayne Chen SR; Oudit GY
Can J Cardiol; 2013 Aug; 29(8):993-6. PubMed ID: 23498838
[TBL] [Abstract][Full Text] [Related]
17. Flecainide therapy suppresses exercise-induced ventricular arrhythmias in patients with CASQ2-associated catecholaminergic polymorphic ventricular tachycardia.
Khoury A; Marai I; Suleiman M; Blich M; Lorber A; Gepstein L; Boulos M
Heart Rhythm; 2013 Nov; 10(11):1671-5. PubMed ID: 23954267
[TBL] [Abstract][Full Text] [Related]
18. A novel RYR2 loss-of-function mutation (I4855M) is associated with left ventricular non-compaction and atypical catecholaminergic polymorphic ventricular tachycardia.
Roston TM; Guo W; Krahn AD; Wang R; Van Petegem F; Sanatani S; Chen SR; Lehman A
J Electrocardiol; 2017; 50(2):227-233. PubMed ID: 27646203
[TBL] [Abstract][Full Text] [Related]
19. Exon 3 deletion of ryanodine receptor causes left ventricular noncompaction, worsening catecholaminergic polymorphic ventricular tachycardia, and sudden cardiac arrest.
Campbell MJ; Czosek RJ; Hinton RB; Miller EM
Am J Med Genet A; 2015 Sep; 167A(9):2197-200. PubMed ID: 26018045
[TBL] [Abstract][Full Text] [Related]
20. Calcium leak through ryanodine receptors leads to atrial fibrillation in 3 mouse models of catecholaminergic polymorphic ventricular tachycardia.
Shan J; Xie W; Betzenhauser M; Reiken S; Chen BX; Wronska A; Marks AR
Circ Res; 2012 Aug; 111(6):708-17. PubMed ID: 22828895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]